LHX8 and hepatocellular carcinoma: PE‐Sor (COL25A1, TGFB1, DACT1, RBP5, PRKD2, GC, ELF5, LHX8 and SCNN1A) was used to predict sorafenib response in hepatocellular carcinoma (HCC) patients.